Study of CM313 in Subject With IgA Nephropathy
NCT06830395
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
106
Enrollment
INDUSTRY
Sponsor class
Conditions
IgA Nephropathy
Interventions
BIOLOGICAL:
CM313
DRUG:
Placebo
Sponsor
Keymed Biosciences Co.Ltd